Hubert Lam

Company: Affini-T Therapeutics

Job title: Scientific co-founder

Seminars:

Enhancing TCR-T Activity through Target Selection, Synthetic Biology, & Non-Viral Gene Editing for Solid Tumor Treatment 1:55 pm

• Discuss how targeting oncodriver mutations for which the cancer has established genetic dependency can limit tumor escape and avoid on-target/off-tumor toxicities • Highlight the incorporation of novel chimeric fusion proteins that can enable TCR-Ts to overcome unfavorable solid tumor microenvironments • Discuss the added benefit of non-viral gene-editing to improve the anti-tumor activity and…Read more

day: Conference Day One

Enhancing TCR-T Activity through Target Selection, Synthetic Biology, & Non-Viral Gene Editing for Solid Tumor Treatment 1:30 pm

Discuss how targeting oncodriver mutations for which the cancer has established genetic dependency can limit tumor escape and avoid on-target/off-tumor toxicities Highlight the incorporation of novel chimeric fusion proteins that can enable TCR-Ts to overcome unfavorable solid tumor microenvironments Discuss the added benefit of non-viral gene-editing to improve the anti-tumor activity and manufacturing of TCR-TsRead more

day: DAY ONE TRACK 2 B

Panel: Navigating Speed & Efficacy: Fast-Tracking TCR Therapy to Clinical Trials with Uncompromised Results 12:00 pm

Discuss streamlined preclinical strategies, such as advanced in vitro models or computational analyses, enabling efficient candidate selection and validation, expediting the transition from bench to bedside Explore approaches in navigating regulatory processes efficiently without compromising safety or efficacy, ensuring compliance while expediting clinical trial initiation Highlight adaptive trial designs or novel methodologies employed in clinical…Read more

day: DAY ONE TRACK 1 B